[Pharmacotherapeutical action on arteriosclerotic vascular diseases with benzarone (author's transl)].
We report the results of a pilot study to evaluate the therapeutical efficiency of Benzarone in a time span of four weeks in 11 male patients with intermittent claudication. Numerous experimental data indicate that there was a statistically significant increase of painless walking distance and a statistically significant decrease of plasma uric acid, cholesterol and triglycerides. Coagulation analyses furthermore show an increase of the factor VIII activity and the plasminogen levels. For the first time, positive results were shown with Benzarone in patients with intermittent claudication.
D001161:Arteriosclerosis / Q000188:drug therapy*; D001553:Benzbromarone / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D005169:Factor VIII; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010958:Plasminogen; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D001572:Benzofurans; D014280:Triglycerides; D014527:Uric Acid; D001553:Benzbromarone; D005169:Factor VIII; D010958:Plasminogen; D002784:Cholesterol
Pharmakotherapeutische Beeinflussung arteriosklerotischer Gefässerkrankungen durch Benzaron.